Targeting of human interleukin-12B by small hairpin RNAs in xenografted psoriatic skin

BMC Dermatology

Volumn 11, Issue , 2011, Pages

  Bak, Rasmus O ^a   Stenderup, Karin ^b   Rosada, Cecilia ^b   Petersen, Line B ^a   Moldt, Brian ^a   Dagnæs Hansen, Frederik ^a   Jakobsen, Maria ^a   Kamp, Søren ^c   Jensen, Thomas G ^a   Dam, Tomas N ^c   Mikkelsen, Jacob G ^a  

^a AARHUS UNIVERSITY   (Denmark)

^b AARHUS UNIVERSITY HOSPITAL   (Denmark)

^c ROSKILDE HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

BETAMETHASONE VALERATE; INTERLEUKIN 12P40; LENTIVIRUS VECTOR; LUCIFERASE; MESSENGER RNA; SHORT HAIRPIN RNA; STELERA; UNCLASSIFIED DRUG; USTEKINUMAB; SMALL INTERFERING RNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DRUG POTENCY; DRUG TARGETING; EPIDERMIS; GENE EXPRESSION; GENE SILENCING; GENE TARGETING; GENETIC TRANSDUCTION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOLOGY; MOUSE; NONHUMAN; PSORIASIS VULGARIS; RNA INTERFERENCE; SCORING SYSTEM; SINGLE DRUG DOSE; TRANSGENE; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; XENOGRAFT; ANIMAL; CELL CULTURE; CELL LINE; CELL STRAIN HEK293; DISEASE MODEL; DOWN REGULATION; DRUG ANTAGONISM; GENE TRANSFER; GENE VECTOR; GENETICS; HELA CELL; INTRADERMAL DRUG ADMINISTRATION; LENTIVIRINAE; MOUSE MUTANT; PLASMID; PSORIASIS;

ANIMALS; CELL LINE; CELLS, CULTURED; DISEASE MODELS, ANIMAL; DOWN-REGULATION; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; HEK293 CELLS; HELA CELLS; HUMANS; INJECTIONS, INTRADERMAL; INTERLEUKIN-12 SUBUNIT P40; LENTIVIRUS; MICE; MICE, SCID; PLASMIDS; PSORIASIS; RNA, MESSENGER; RNA, SMALL INTERFERING; TRANSPLANTATION, HETEROLOGOUS;

EID: 79951944452     PISSN: None     EISSN: 14715945     Source Type: Journal    
DOI: 10.1186/1471-5945-11-5     Document Type: Article

References (44)

1. Schon MP, Boehncke WH. Psoriasis. N Engl J Med 2005, 352:1899-1912. 10.1056/NEJMra041320, 15872205.
2. Griffiths CE, Barker JN. Pathogenesis and clinical features of psoriasis. Lancet 2007, 370:263-271. 10.1016/S0140-6736(07)61128-3, 17658397.
3. Kurd SK, Gelfand JM. The prevalence of previously diagnosed and undiagnosed psoriasis in US adults: results from NHANES 2003-2004. J Am Acad Dermatol 2009, 60:218-224. 10.1016/j.jaad.2008.09.022, 19022533.
4. Hong J, Koo B, Koo J. The psychosocial and occupational impact of chronic skin disease. Dermatol Ther 2008, 21:54-59. 10.1111/j.1529-8019.2008.00170.x, 18318886.
5. Zachariae R, Zachariae H, Blomqvist K, Davidsson S, Molin L, Mork C, Sigurgeirsson B. Quality of life in 6497 Nordic patients with psoriasis. Br J Dermatol 2002, 146:1006-1016. 10.1046/j.1365-2133.2002.04742.x, 12072069.
6. Ghoreschi K, Thomas P, Breit S, Dugas M, Mailhammer R, van Eden W, van der Zee R, Biedermann T, Prinz J, Mack M, et al. Interleukin-4 therapy of psoriasis induces Th2 responses and improves human autoimmune disease. Nat Med 2003, 9:40-46. 10.1038/nm804, 12461524.
7. Stenderup K, Rosada C, Worsaae A, Dagnaes-Hansen F, Steiniche T, Hasselager E, Iversen LF, Zahn S, Woldike H, Holmberg HL, et al. Interleukin-20 plays a critical role in maintenance and development of psoriasis in the human xenograft transplantation model. Br J Dermatol 2009, 160:284-296. 10.1111/j.1365-2133.2008.08890.x, 18945296.
8. Jakobsen M, Stenderup K, Rosada C, Moldt B, Kamp S, Dam TN, Jensen TG, Mikkelsen JG. Amelioration of psoriasis by anti-TNF-alpha RNAi in the xenograft transplantation model. Mol Ther 2009, 17:1743-1753. 10.1038/mt.2009.141, 2835022, 19568223.
9. Villadsen LS, Schuurman J, Beurskens F, Dam TN, Dagnaes-Hansen F, Skov L, Rygaard J, Voorhorst-Ogink MM, Gerritsen AF, van Dijk MA, et al. Resolution of psoriasis upon blockade of IL-15 biological activity in a xenograft mouse model. J Clin Invest 2003, 112:1571-1580. 259129, 14617758.
10. Caruso R, Botti E, Sarra M, Esposito M, Stolfi C, Diluvio L, Giustizieri ML, Pacciani V, Mazzotta A, Campione E, et al. Involvement of interleukin-21 in the epidermal hyperplasia of psoriasis. Nat Med 2009, 15:1013-1015. 10.1038/nm.1995, 19684581.
11. Schopf RE, Aust H, Knop J. Treatment of psoriasis with the chimeric monoclonal antibody against tumor necrosis factor alpha, infliximab. J Am Acad Dermatol 2002, 46:886-891. 10.1067/mjd.2002.120472, 12063486.
12. Mease PJ, Goffe BS, Metz J, VanderStoep A, Finck B, Burge DJ. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet 2000, 356:385-390. 10.1016/S0140-6736(00)02530-7, 10972371.
13. Menter A, Tyring SK, Gordon K, Kimball AB, Leonardi CL, Langley RG, Strober BE, Kaul M, Gu Y, Okun M, Papp K. Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial. J Am Acad Dermatol 2008, 58:106-115. 10.1016/j.jaad.2007.09.010, 17936411.
14. Arican O, Aral M, Sasmaz S, Ciragil P. Serum levels of TNF-alpha, IFN-gamma, IL-6, IL-8, IL-12, IL-17, and IL-18 in patients with active psoriasis and correlation with disease severity. Mediators Inflamm 2005, 2005:273-279. 10.1155/MI.2005.273, 1533889, 16258194.
15. Lee E, Trepicchio WL, Oestreicher JL, Pittman D, Wang F, Chamian F, Dhodapkar M, Krueger JG. Increased expression of interleukin 23 p19 and p40 in lesional skin of patients with psoriasis vulgaris. J Exp Med 2004, 199:125-130. 10.1084/jem.20030451, 1887731, 14707118.
16. Yawalkar N, Tscharner GG, Hunger RE, Hassan AS. Increased expression of IL-12p70 and IL-23 by multiple dendritic cell and macrophage subsets in plaque psoriasis. J Dermatol Sci 2009, 54:99-105. 10.1016/j.jdermsci.2009.01.003, 19264456.
17. Tonel G, Conrad C, Laggner U, Di Meglio P, Grys K, McClanahan TK, Blumenschein WM, Qin JZ, Xin H, Oldham E, et al. Cutting Edge: A Critical Functional Role for IL-23 in Psoriasis. J Immunol 2010, 185:5688-5691. 10.4049/jimmunol.1001538, 20956338.
18. Gerosa F, Baldani-Guerra B, Lyakh LA, Batoni G, Esin S, Winkler-Pickett RT, Consolaro MR, De Marchi M, Giachino D, Robbiano A, et al. Differential regulation of interleukin 12 and interleukin 23 production in human dendritic cells. J Exp Med 2008, 205:1447-1461. 10.1084/jem.20071450, 2413040, 18490488.
19. Piskin G, Sylva-Steenland RM, Bos JD, Teunissen MB. In vitro and in situ expression of IL-23 by keratinocytes in healthy skin and psoriasis lesions: enhanced expression in psoriatic skin. J Immunol 2006, 176:1908-1915.
20. Trinchieri G. Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev Immunol 2003, 3:133-146. 10.1038/nri1001, 12563297.
21. Cargill M, Schrodi SJ, Chang M, Garcia VE, Brandon R, Callis KP, Matsunami N, Ardlie KG, Civello D, Catanese JJ, et al. A large-scale genetic association study confirms IL12B and leads to the identification of IL23R as psoriasis-risk genes. Am J Hum Genet 2007, 80:273-290. 10.1086/511051, 1785338, 17236132.
22. Piskin G, Tursen U, Sylva-Steenland RM, Bos JD, Teunissen MB. Clinical improvement in chronic plaque-type psoriasis lesions after narrow-band UVB therapy is accompanied by a decrease in the expression of IFN-gamma inducers -- IL-12, IL-18 and IL-23. Exp Dermatol 2004, 13:764-772. 10.1111/j.0906-6705.2004.00246.x, 15560760.
23. Gottlieb AB, Chamian F, Masud S, Cardinale I, Abello MV, Lowes MA, Chen F, Magliocco M, Krueger JG. TNF inhibition rapidly down-regulates multiple proinflammatory pathways in psoriasis plaques. J Immunol 2005, 175:2721-2729.
24. Chamian F, Lowes MA, Lin SL, Lee E, Kikuchi T, Gilleaudeau P, Sullivan-Whalen M, Cardinale I, Khatcherian A, Novitskaya I, et al. Alefacept reduces infiltrating T cells, activated dendritic cells, and inflammatory genes in psoriasis vulgaris. Proc Natl Acad Sci USA 2005, 102:2075-2080. 10.1073/pnas.0409569102, 545584, 15671179.
25. van de Kerkhof PC. Novel biologic therapies in development targeting IL-12/IL-23. J Eur Acad Dermatol Venereol 2010, 24(Suppl 6):5-9. 10.1111/j.1468-3083.2010.03830.x, 20831703.
26. Trial watch: novel biologic for psoriasis shows superiority over current best-seller. Nat Rev Drug Discov 2008, 7:880-881.
27. Fire A, Xu S, Montgomery MK, Kostas SA, Driver SE, Mello CC. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 1998, 391:806-811. 10.1038/35888, 9486653.
28. Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K, Tuschl T. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 2001, 411:494-498. 10.1038/35078107, 11373684.
29. Brummelkamp TR, Bernards R, Agami R. A system for stable expression of short interfering RNAs in mammalian cells. Science 2002, 296:550-553. 10.1126/science.1068999, 11910072.
30. Abbas-Terki T, Blanco-Bose W, Deglon N, Pralong W, Aebischer P. Lentiviral-mediated RNA interference. Hum Gene Ther 2002, 13:2197-2201. 10.1089/104303402320987888, 12542850.
31. Dam TN, Kang S, Nickoloff BJ, Voorhees JJ. 1alpha,25-dihydroxycholecalciferol and cyclosporine suppress induction and promote resolution of psoriasis in human skin grafts transplanted on to SCID mice. J Invest Dermatol 1999, 113:1082-1089. 10.1046/j.1523-1747.1999.00811.x, 10594756.
32. Raoul C, Abbas-Terki T, Bensadoun JC, Guillot S, Haase G, Szulc J, Henderson CE, Aebischer P. Lentiviral-mediated silencing of SOD1 through RNA interference retards disease onset and progression in a mouse model of ALS. Nat Med 2005, 11:423-428. 10.1038/nm1207, 15768028.
33. Moldt B, Staunstrup NH, Jakobsen M, Yanez-Munoz RJ, Mikkelsen JG. Genomic insertion of lentiviral DNA circles directed by the yeast Flp recombinase. BMC Biotechnol 2008, 8:60. 10.1186/1472-6750-8-60, 2538528, 18691430.
34. McIntyre GJ, Fanning GC. Design and cloning strategies for constructing shRNA expression vectors. BMC Biotechnol 2006, 6:1. 10.1186/1472-6750-6-1, 1343552, 16396676.
35. Baer M, Nilsen TW, Costigan C, Altman S. Structure and transcription of a human gene for H1 RNA, the RNA component of human RNase P. Nucleic Acids Res 1990, 18:97-103. 10.1093/nar/18.1.97, 330208, 2308839.
36. Flynn MA, Casey DG, Todryk SM, Mahon BP. Efficient delivery of small interfering RNA for inhibition of IL-12p40 expression in vivo. J Inflamm (Lond) 2004, 1:4. 10.1186/1476-9255-1-4, 1074346, 15813981.
37. Borg C, Jalil A, Laderach D, Maruyama K, Wakasugi H, Charrier S, Ryffel B, Cambi A, Figdor C, Vainchenker W, et al. NK cell activation by dendritic cells (DCs) requires the formation of a synapse leading to IL-12 polarization in DCs. Blood 2004, 104:3267-3275. 10.1182/blood-2004-01-0380, 15242871.
38. de Jongh GJ, Zeeuwen PL, Kucharekova M, Pfundt R, van der Valk PG, Blokx W, Dogan A, Hiemstra PS, van de Kerkhof PC, Schalkwijk J. High expression levels of keratinocyte antimicrobial proteins in psoriasis compared with atopic dermatitis. J Invest Dermatol 2005, 125:1163-1173. 10.1111/j.0022-202X.2005.23935.x, 16354186.
39. Thakker DR, Natt F, Husken D, Maier R, Muller M, van der Putten H, Hoyer D, Cryan JF. Neurochemical and behavioral consequences of widespread gene knockdown in the adult mouse brain by using nonviral RNA interference. Proc Natl Acad Sci USA 2004, 101:17270-17275. 10.1073/pnas.0406214101, 535368, 15569935.
40. Ivics Z, Hackett PB, Plasterk RH, Izsvak Z. Molecular reconstruction of Sleeping Beauty, a Tc1-like transposon from fish, and its transposition in human cells. Cell 1997, 91:501-510. 10.1016/S0092-8674(00)80436-5, 9390559.
41. Boehncke WH. The psoriasis SCID mouse model: a tool for drug discovery?. Ernst Schering Res Found Workshop 2005, 213-234. full_text, 15526945.
42. Traub M, Marshall K. Psoriasis--pathophysiology, conventional, and alternative approaches to treatment. Altern Med Rev 2007, 12:319-330.
43. Nickoloff BJ, Karabin GD, Barker JN, Griffiths CE, Sarma V, Mitra RS, Elder JT, Kunkel SL, Dixit VM. Cellular localization of interleukin-8 and its inducer, tumor necrosis factor-alpha in psoriasis. Am J Pathol 1991, 138:129-140. 1886036, 1702929.
44. Takanashi M, Oikawa K, Sudo K, Tanaka M, Fujita K, Ishikawa A, Nakae S, Kaspar RL, Matsuzaki M, Kudo M, Kuroda M. Therapeutic silencing of an endogenous gene by siRNA cream in an arthritis model mouse. Gene Ther 2009, 16:982-989. 10.1038/gt.2009.66, 19474812.